(201 days)
The EXPEDIUM™ Spine System is intended for noncervical pedicle fixation and nonpedicle fixation for the following indications: degenerative disc disease (defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies); spondylolisthesis; trauma (i.e., fracture or dislocation); spinal stenosis; curvatures (i.e., scoliosis, kyphosis, and/or lordosis); tumor; pseudoarthrosis; and failed previous fusion in skeletally mature patients.
The subject EXPEDIUM™ Spine System rods are designed to work in conjunction with the components of the following DePuy Spine spine systems: EXPEDIUM™ 6.35mm Spine System (Ti + SS), EXPEDIUM™ 5.5mm Spine System (Ti + SS), ISOLA® 4.75mm Spine System (Ti + SS), ISOLA® 6.35mm Spine System (Ti + SS), MONARCH™ 5.5mm Spine System (Ti), MONARCH™ 6.35mm Spine System (Ti), MOSS MIAMI™ 5.0mm Spine System (SS), MOSS MIAMITM 5.5mm Spine System (Ti), MOSS MIAMI™ 6.35mm Spine System (SS), VIPERTM 5.5mm Spine System (Ti). Manufactured from ASTM F 138 implant grade stainless steel and ASTM F 136 implant grade titanium alloy.
The provided document is a 510(k) summary for the EXPEDIUM™ Spine System, a medical device for spinal fixation. It describes the device, its intended use, materials, and a declaration of substantial equivalence to predicate devices, noting performance data per ASTM F 1717.
However, the document does not contain the information requested in the prompt regarding acceptance criteria and a study proving the device meets those criteria, specifically for diagnostic or AI-assisted devices.
The product is a physical orthotic system, not a diagnostic device or an AI/software product that would typically have acceptance criteria related to performance metrics like sensitivity, specificity, or reader improvement. The "performance data" mentioned refers to mechanical testing (ASTM F 1717) for the physical components of the spinal system, not clinical or diagnostic performance criteria.
Therefore, I cannot fulfill the request for a table of acceptance criteria and reported device performance using the provided text, as this information is not present. The questions about sample sizes for test sets, data provenance, number of experts, adjudication methods, MRMC studies, standalone performance, type of ground truth, and training set information are all pertinent to the evaluation of AI or diagnostic devices, which this product is not.
{0}------------------------------------------------
510(K) SUMMARY 6.
| Submitter: | DePuy Spine, Inc.325 Paramount DriveRaynham, MA 02767 | JUL 10 2007 |
|---|---|---|
| Contact Person: | Christopher Klaczyk, Regulatory Project ManagerVoice: (508) 828-2852Fax: (508) 828-3797 | |
| Date Prepared: | December 20, 2006 | |
| Device Class: | Class III | |
| Classification Name: | Spinal interlaminar fixation orthosisper 21 CFR §888.3050 |
Spinal intervertebral body fixation orthosis per 21 CFR §888.3060
Pedicle screw spinal fixation per 21 CFR §888.3070
Classification Panel: Orthopedics
FDA Panel Number: 87
| Product Code(s): | KWP, MNH, MNI, NKB, KWQ |
|---|---|
| Proprietary Name: | EXPEDIUM™ Spine System |
| Predicate Devices: | EXPEDIUM™ Spine System (K033901, K041119,K062174, K063156)MONARCH™ Spine System (K024348)ISOLA® Spine System (K952236, K980485) |
| Device Description: | The subject EXPEDIUM™ Spine System rods are designedto work in conjunction with the components of thefollowing DePuy Spine spine systems:EXPEDIUM™ 6.35mm Spine System (Ti + SS)EXPEDIUM™ 5.5mm Spine System (Ti + SS)ISOLA® 4.75mm Spine System (Ti + SS)ISOLA® 6.35mm Spine System (Ti + SS)MONARCH™ 5.5mm Spine System (Ti)MONARCH™ 6.35mm Spine System (Ti)MOSS MIAMI™ 5.0mm Spine System (SS) |
Kob 3772 Page 1 of 2
{1}------------------------------------------------
MOSS MIAMITM 5.5mm Spine System (Ti) MOSS MIAMI™ 6.35mm Spine System (SS) VIPERTM 5.5mm Spine System (Ti)
- The EXPEDIUM Spine System is intended for noncervical Intended Use: pedicle fixation and nonpedicle fixation for the following indications: degenerative disc disease (defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies); spondylolisthesis; trauma (i.e., fracture or dislocation); spinal stenosis; curvatures (i.e., scoliosis, kyphosis, and/or lordosis); tumor; pseudoarthrosis; and failed previous fusion in skeletally mature patients. Manufactured from ASTM F 138 implant grade stainless Materials: steel and ASTM F 136 implant grade titanium alloy. Performance data per ASTM F 1717 were submitted to Performance Data: characterize the subject EXPEDIUM™ Spine System
components addressed in this notification.
{2}------------------------------------------------
Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized depiction of an eagle or bird-like figure with three curved lines representing its body and wings. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the bird symbol.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
DePuy Spine, Incorporated c/o Mr. Christopher Klaczyk Regulatory Project Manager 325 Paramount Drive Raynham, Massachusetts 02767-0350
JUL 1 0 2007
Re: K063772
Trade/Device Name: EXPEDIUM™ Spine System Regulation Number: 21 CFR 888.3070 Regulation Name: Pedicle screw spinal system Regulatory Class: Class III Product Code: NKB, MNI, MNH, KWP and KWQ Dated: May 31, 2007 Received: May 31, 2007
Dear Mr. Klaczyk:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. .
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
{3}------------------------------------------------
Page 2 - Mr. Christopher Klaczyk
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at toll-free number (800) 638-2041 or (240) 276-3150 or the Internet address http://www.fda.gov/cdrh/industry/support/index.html
Sincerely vours.
Boubeau Buehup
for
Mark N. Me kerson Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{4}------------------------------------------------
Special 510(k) Submission - Additions to EXPEDIUM™ Spine System
INDICATIONS FOR USE STATEMENT 5.
063772 510(k) Number (if known):
Device Name: EXPEDIUM™ Spine System
Indications For Use:
The EXPEDIUM™ Spine System is intended for noncervical pedicle fixation and nonpedicle fixation for the following indications: degenerative disc disease (defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies); spondylolisthesis; trauma (i.e., fracture or dislocation); spinal stenosis; curvatures (i.e., scoliosis, kyphosis, and/or lordosis); tumor; pseudarthrosis; and failed previous fusion in skeletally mature patients.
Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Barbara Boehme
neral, Restorative. and Neurological Devices
510(k) Number K063772
§ 888.3070 Thoracolumbosacral pedicle screw system.
(a)
Identification. (1) Rigid pedicle screw systems are comprised of multiple components, made from a variety of materials that allow the surgeon to build an implant system to fit the patient's anatomical and physiological requirements. Such a spinal implant assembly consists of a combination of screws, longitudinal members (e.g., plates, rods including dual diameter rods, plate/rod combinations), transverse or cross connectors, and interconnection mechanisms (e.g., rod-to-rod connectors, offset connectors).(2) Semi-rigid systems are defined as systems that contain one or more of the following features (including but not limited to): Non-uniform longitudinal elements, or features that allow more motion or flexibility compared to rigid systems.
(b)
Classification. (1) Class II (special controls), when intended to provide immobilization and stabilization of spinal segments in skeletally mature patients as an adjunct to fusion in the treatment of the following acute and chronic instabilities or deformities of the thoracic, lumbar, and sacral spine: severe spondylolisthesis (grades 3 and 4) of the L5-S1 vertebra; degenerative spondylolisthesis with objective evidence of neurologic impairment; fracture; dislocation; scoliosis; kyphosis; spinal tumor; and failed previous fusion (pseudarthrosis). These pedicle screw spinal systems must comply with the following special controls:(i) Compliance with material standards;
(ii) Compliance with mechanical testing standards;
(iii) Compliance with biocompatibility standards; and
(iv) Labeling that contains these two statements in addition to other appropriate labeling information:
“Warning: The safety and effectiveness of pedicle screw spinal systems have been established only for spinal conditions with significant mechanical instability or deformity requiring fusion with instrumentation. These conditions are significant mechanical instability or deformity of the thoracic, lumbar, and sacral spine secondary to severe spondylolisthesis (grades 3 and 4) of the L5-S1 vertebra, degenerative spondylolisthesis with objective evidence of neurologic impairment, fracture, dislocation, scoliosis, kyphosis, spinal tumor, and failed previous fusion (pseudarthrosis). The safety and effectiveness of these devices for any other conditions are unknown.”
“Precaution: The implantation of pedicle screw spinal systems should be performed only by experienced spinal surgeons with specific training in the use of this pedicle screw spinal system because this is a technically demanding procedure presenting a risk of serious injury to the patient.”
(2) Class II (special controls), when a rigid pedicle screw system is intended to provide immobilization and stabilization of spinal segments in the thoracic, lumbar, and sacral spine as an adjunct to fusion in the treatment of degenerative disc disease and spondylolisthesis other than either severe spondylolisthesis (grades 3 and 4) at L5-S1 or degenerative spondylolisthesis with objective evidence of neurologic impairment. These pedicle screw systems must comply with the following special controls:
(i) The design characteristics of the device, including engineering schematics, must ensure that the geometry and material composition are consistent with the intended use.
(ii) Non-clinical performance testing must demonstrate the mechanical function and durability of the implant.
(iii) Device components must be demonstrated to be biocompatible.
(iv) Validation testing must demonstrate the cleanliness and sterility of, or the ability to clean and sterilize, the device components and device-specific instruments.
(v) Labeling must include the following:
(A) A clear description of the technological features of the device including identification of device materials and the principles of device operation;
(B) Intended use and indications for use, including levels of fixation;
(C) Identification of magnetic resonance (MR) compatibility status;
(D) Cleaning and sterilization instructions for devices and instruments that are provided non-sterile to the end user; and
(E) Detailed instructions of each surgical step, including device removal.
(3) Class II (special controls), when a semi-rigid system is intended to provide immobilization and stabilization of spinal segments in the thoracic, lumbar, and sacral spine as an adjunct to fusion for any indication. In addition to complying with the special controls in paragraphs (b)(2)(i) through (v) of this section, these pedicle screw systems must comply with the following special controls:
(i) Demonstration that clinical performance characteristics of the device support the intended use of the product, including assessment of fusion compared to a clinically acceptable fusion rate.
(ii) Semi-rigid systems marketed prior to the effective date of this reclassification must submit an amendment to their previously cleared premarket notification (510(k)) demonstrating compliance with the special controls in paragraphs (b)(2)(i) through (v) and paragraph (b)(3)(i) of this section.